Mirvetuximab soravtansine was approved as a first-in-class antibody–drug conjugate targeting folate receptor alpha for the treatment of adult patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously underwent one to three systemic treatment regimens [141]. This evidence concerns the gene FOLR1 and peritoneum cancer.